Table 1 DDX3 expression in cancer patients

Breast cancer

366

-

-

20 %

35 %

HR 2.01 (95 % CI; 0.99–4.08)

[45]

152

-

-

-

45 %

HR 2.06 (RNA-seq)*

[79]

Lung cancer

144

-

47 %

-

53 %

HR 0.62 (95 % CI; 0.40–0.96)

DDX3 association with:

[59, 76]

E-cadherin (OR=3.32; p=0.007), p21 (OR=3.25; p=0.001), HPV (OR=0.30; p=0.002)

95

-

-

5 %

66 %

HR 2.10 (95 % CI; 1.13–3.93)

[47]

Colon cancer

221

-

-

-

60 %

HR 0.45 (95 % CI; 0.31–0.65)

inverse association with metastasis (RR=0.44; p=0.005)

[79]

303

-

-

-

41 %

-

DDX association with nuclear β-catenin (RR=1.77; p<0.001)

[92]

Gallbladder cancer

126

-

-

-

55 %

15 months (low DDX3) vs 7 months (high DDX3)#

[81]

Liver cancer

45

-

64 %

-

-

-

[65]

26

-

9 %

-

4 %

-

[24]

41

-

-

-

19 %

no prognostic significance

[68]

Head and neck cancer

324

-

-

11 %

HR 0.23 (95 % CI; 0.07–0.75) – non-smokers

decrease of nuclear expression, increase of cytoplasmic expression in dysplastic epithelium

[77]

(nuclear or cytoplasmic)

HR 1.12 (95 % CI; 0.41–3.04) – smokers

423

-

-

-

51 %

HR 0.88 (95 % CI; 0.53–1.45) – non-smokers

[78]

HR 1.34 (95 % CI; 1.00–1.81) – smokers

107

-

-

-

47 %

no prognostic significance

[79]

74

4 %

-

-

-

-

not evidently HPV dependent, mutations in oropharyngeal cancer

[84]

51

8 %

-

-

-

-

probably loss of function mutation

[90]

69

0 %

-

-

-

-

[90]

50

10 %

-

-

-

-

homozygous deletions, not evidently HPV dependent

[91]

Skin cancer

34

-

-

decreased nuclear and increased cytoplasmic DDX3 expression compared to normal

-

[24]

Brain cancer

92

8 %

-

-

-

-

probably gain of function mutation, association with WNT subtype (50 % of WNT subtype has DDX3 mutation)

[72]

31

-

-

52 % (western blot)

-

association between DDX3 and snail (p=0.001)

[75]

Leukemia

91

3 %

-

-

-

-

[85]